Secreted frizzled related protein-1 (sFRP-1) inhibitors have the potential to be used for the treatment of osteoporosis or other bone related disorders, since the level of sFRP-1 affects osteoblast apoptosis and proliferation. From high throughput screening, we have identified a class of iminooxothiazolidines as sFRP-1 inhibitors. Structure–activity relationships were established for various regions of the scaffold along with the biochemical characterization ...
![(2E)-4-[(3-Cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-4 -oxo-2-butenoic acid Structure](https://image.chemsrc.com/caspic/019/299953-51-8.png)